Orphan status awarded for gallium-68 DOTATATE

03/4/2014 | News-Medical.Net

Advanced Accelerator Applications' gallium-68 DOTATATE, a radiopharmaceutical used in PET/CT imaging of gastro-entero-pancreatic neuroendocrine tumors, has been granted orphan drug status by the FDA and the European Medicines Agency. Preliminary data suggest the agent will improve cancer diagnosis while reducing radiation exposure.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA